Gerostate Alpha
Biotechnology
High-throughput phenotypic screening for drugs that extend lifespan
Novato, CA
Claim This ListingIntervene Immune Inc. is based in Torrance, CA, founded in 2016 and is listed under Biotechnology.
Longevity biotechnology company reversing age-related immune decline through thymus regeneration and regenerative therapies.
Is this your company or organization? Claim your free listing to manage your profile, update your information, and increase your visibility across the longevity economy.
Intervene Immune is a pioneering longevity biotechnology company focused on reversing age-related immune system decline through thymus regeneration and advanced regenerative therapies. Led by co-founders Dr. Gregory Fahy and Robert Brooke, the company is developing innovative treatments to combat immunosenescence — the progressive deterioration of immune function associated with aging. Its research centers on regenerating the thymus, a vital organ responsible for producing T cells that help protect the body against infections and disease. As people age, the thymus naturally shrinks, reducing the immune system's ability to produce new T cells. Intervene Immune gained international attention through its landmark TRIIM clinical trial, published in Aging Cell in 2019. The small preliminary study reported evidence of thymus regeneration and improvements in biological aging biomarkers, including an average reduction of approximately 2.5 years in measured epigenetic age after one year of treatment. The company is advancing this research through its expanded TRIIM-X clinical trial, which investigates personalized treatment protocols combining growth hormone and other medications, supported by comprehensive immune profiling and biological age monitoring. Intervene Immune is also developing advanced immune diagnostic services and next-generation therapeutics designed to restore immune function and potentially improve healthspan. Scientific significance: Intervene Immune represents an innovative approach to longevity medicine by targeting immune system aging rather than individual age-related diseases. While early human results are promising, larger controlled clinical trials are needed to establish long-term safety, clinical effectiveness, and whether these interventions can extend human healthspan or lifespan.
Biotechnology
High-throughput phenotypic screening for drugs that extend lifespan
Novato, CA
Claim This ListingBiotechnology
AI drug discovery
San Carlos, CA
Claim This ListingBiotechnology
DNA minicircles for gene expression
Austin, TX
Claim This Listing